Efficacy and safety of alemtuzumab versus fingolimod in RRMS after natalizumab cessation
BackgroundNatalizumab (NTZ) was the first approved monoclonal antibody for the treatment of relapsing-remitting multiple sclerosis (RRMS). Despite proven and sustained efficacy, its use is limited by the risk of progressive multifocal leukoencephalopathy (PML). Moreover, some patients show ongoing d...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2019
|
| In: |
Journal of neurology
Year: 2018, Volume: 266, Issue: 1, Pages: 165-173 |
| ISSN: | 1432-1459 |
| DOI: | 10.1007/s00415-018-9117-z |
| Online Access: | Verlag, Volltext: https://doi.org/10.1007/s00415-018-9117-z
|
| Author Notes: | Steffen Pfeuffer, Rene Schmidt, Frederike Anne Straeten, Refik Pul, Christoph Kleinschnitz, Marinus Wieshuber, De-Hyung Lee, Ralf A. Linker, Sebastian Doerck, Vera Straeten, Susanne Windhagen, Marc Pawlitzki, Christoph Aufenberg, Michael Lang, Christian Eienbroeker, Björn Tackenberg, Volker Limmroth, Brigitte Wildemann, Jürgen Haas, Luisa Klotz, Heinz Wiendl, Tobias Ruck, Sven G. Meuth |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1668943085 | ||
| 003 | DE-627 | ||
| 005 | 20230427221806.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 190710r20192018xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00415-018-9117-z |2 doi | |
| 035 | |a (DE-627)1668943085 | ||
| 035 | |a (DE-599)KXP1668943085 | ||
| 035 | |a (OCoLC)1341233265 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Pfeuffer, Steffen |e VerfasserIn |0 (DE-588)1190239914 |0 (DE-627)166894295X |4 aut | |
| 245 | 1 | 0 | |a Efficacy and safety of alemtuzumab versus fingolimod in RRMS after natalizumab cessation |c Steffen Pfeuffer, Rene Schmidt, Frederike Anne Straeten, Refik Pul, Christoph Kleinschnitz, Marinus Wieshuber, De-Hyung Lee, Ralf A. Linker, Sebastian Doerck, Vera Straeten, Susanne Windhagen, Marc Pawlitzki, Christoph Aufenberg, Michael Lang, Christian Eienbroeker, Björn Tackenberg, Volker Limmroth, Brigitte Wildemann, Jürgen Haas, Luisa Klotz, Heinz Wiendl, Tobias Ruck, Sven G. Meuth |
| 264 | 1 | |c 2019 | |
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Published online: 16 November 2018 | ||
| 500 | |a Gesehen am 10.07.2019 | ||
| 520 | |a BackgroundNatalizumab (NTZ) was the first approved monoclonal antibody for the treatment of relapsing-remitting multiple sclerosis (RRMS). Despite proven and sustained efficacy, its use is limited by the risk of progressive multifocal leukoencephalopathy (PML). Moreover, some patients show ongoing disease activity under NTZ, requiring a switch to another disease-modifying treatment (DMT). However, evidence regarding the optimal DMT for treatment of active RRMS after NTZ-cessation is still scarce.ObjectiveTo evaluate efficacy and safety outcomes of ALEM vs FTY treatment after cessation of NTZ.MethodsWe retrospectively identified patients at 12 German neurology centers and analyzed risks for disease activity, adverse events, disability progression, and treatment discontinuation.Results195 patients were identified and 144 underwent final analysis (FTY: 101; ALEM: 42). The hazard ratio for clinical relapses was 2.24 favoring ALEM (95% CI 1.12-4.50; p = 0.015). The hazard ratio for adverse events was 7.78 (95% CI 1.04-57.95; p = 0.006) and 2.41 for MRI progression (95% CI 1.26-4.60; p = 0.004). The odds ratio for disability progression after 12 months was 4.84 (95% CI 1.74-13.47, p = 0.003). Differences remained after adjusting for possible confounders (e.g., age, sex, baseline disability, NTZ treatment duration, washout time).ConclusionOur findings indicated particular advantages of ALEM compared to FTY in patients stopping NTZ. | ||
| 534 | |c 2018 | ||
| 650 | 4 | |a Alemtuzumab | |
| 650 | 4 | |a Fingolimod | |
| 650 | 4 | |a Immunomodulatory therapy | |
| 650 | 4 | |a Natalizumab | |
| 650 | 4 | |a Progressive multifocal leukoencephalopathy | |
| 650 | 4 | |a Remitting-relapsing multiple sclerosis | |
| 700 | 1 | |a Schmidt, René |d 1981- |e VerfasserIn |0 (DE-588)135959519 |0 (DE-627)693928433 |0 (DE-576)284895695 |4 aut | |
| 700 | 1 | |a Straeten, Frederike Anne |e VerfasserIn |4 aut | |
| 700 | 1 | |a Pul, Refik |d 1975- |e VerfasserIn |0 (DE-588)13323293X |0 (DE-627)539304522 |0 (DE-576)299712877 |4 aut | |
| 700 | 1 | |a Kleinschnitz, Christoph |d 1973- |e VerfasserIn |0 (DE-588)123343909 |0 (DE-627)082497966 |0 (DE-576)293666032 |4 aut | |
| 700 | 1 | |a Wieshuber, Marinus |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lee, De-Hyung |d 1974- |e VerfasserIn |0 (DE-588)138436525 |0 (DE-627)602585163 |0 (DE-576)307570096 |4 aut | |
| 700 | 1 | |a Linker, Ralf |d 1971- |e VerfasserIn |0 (DE-588)122044371 |0 (DE-627)705749568 |0 (DE-576)29306413X |4 aut | |
| 700 | 1 | |a Doerck, Sebastian |d 1979- |e VerfasserIn |0 (DE-588)13319664X |0 (DE-627)538270349 |0 (DE-576)299686981 |4 aut | |
| 700 | 1 | |a Straeten, Vera |e VerfasserIn |4 aut | |
| 700 | 1 | |a Windhagen, Susanne |d 1971- |e VerfasserIn |0 (DE-588)121125904 |0 (DE-627)705245373 |0 (DE-576)29254930X |4 aut | |
| 700 | 1 | |a Pawlitzki, Marc |e VerfasserIn |0 (DE-588)1155421779 |0 (DE-627)1017709602 |0 (DE-576)501630686 |4 aut | |
| 700 | 1 | |a Aufenberg, Christoph |d 1974- |e VerfasserIn |0 (DE-588)128667567 |0 (DE-627)377439061 |0 (DE-576)297268945 |4 aut | |
| 700 | 1 | |a Lang, Michael |e VerfasserIn |4 aut | |
| 700 | 1 | |a Eienbroeker, Christian |e VerfasserIn |4 aut | |
| 700 | 1 | |a Tackenberg, Björn |e VerfasserIn |0 (DE-588)1114091626 |0 (DE-627)868034959 |0 (DE-576)47720886X |4 aut | |
| 700 | 1 | |a Limmroth, Volker |e VerfasserIn |0 (DE-588)113072570 |0 (DE-627)521941318 |0 (DE-576)289751152 |4 aut | |
| 700 | 1 | |a Wildemann, Brigitte |e VerfasserIn |0 (DE-588)110203844 |0 (DE-627)510150004 |0 (DE-576)171831330 |4 aut | |
| 700 | 1 | |a Haas, Jürgen |e VerfasserIn |0 (DE-588)1073216810 |0 (DE-627)828662290 |0 (DE-576)434731749 |4 aut | |
| 700 | 1 | |a Klotz, Luisa |d 1975- |e VerfasserIn |0 (DE-588)123099781 |0 (DE-627)082347034 |0 (DE-576)293555591 |4 aut | |
| 700 | 1 | |a Wiendl, Heinz |d 1968- |e VerfasserIn |0 (DE-588)131501097 |0 (DE-627)510152694 |0 (DE-576)257377336 |4 aut | |
| 700 | 1 | |a Ruck, Tobias |d 1985- |e VerfasserIn |0 (DE-588)1050955498 |0 (DE-627)78531282X |0 (DE-576)40539862X |4 aut | |
| 700 | 1 | |a Meuth, Sven G. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of neurology |d [Darmstadt] : Steinkopff, 1974 |g 266(2019), 1, Seite 165-173 |h Online-Ressource |w (DE-627)242065155 |w (DE-600)1421299-7 |w (DE-576)065026500 |x 1432-1459 |7 nnas |a Efficacy and safety of alemtuzumab versus fingolimod in RRMS after natalizumab cessation |
| 773 | 1 | 8 | |g volume:266 |g year:2019 |g number:1 |g pages:165-173 |g extent:9 |a Efficacy and safety of alemtuzumab versus fingolimod in RRMS after natalizumab cessation |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s00415-018-9117-z |x Verlag |x Resolving-System |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20190710 | ||
| 993 | |a Article | ||
| 994 | |a 2019 | ||
| 998 | |g 1073216810 |a Haas, Jürgen |m 1073216810:Haas, Jürgen |d 910000 |d 911100 |e 910000PH1073216810 |e 911100PH1073216810 |k 0/910000/ |k 1/910000/911100/ |p 19 | ||
| 998 | |g 110203844 |a Wildemann, Brigitte |m 110203844:Wildemann, Brigitte |d 910000 |d 911100 |e 910000PW110203844 |e 911100PW110203844 |k 0/910000/ |k 1/910000/911100/ |p 18 | ||
| 999 | |a KXP-PPN1668943085 |e 3492494692 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"type":{"bibl":"article-journal","media":"Online-Ressource"},"relHost":[{"title":[{"title_sort":"Journal of neurology","title":"Journal of neurology"}],"note":["Gesehen am 14.03.25","Ungezählte Beil.: Supplement"],"pubHistory":["Volume 207, issue 1 (March 1974)-"],"origin":[{"dateIssuedDisp":"1974-","publisher":"Steinkopff ; Springer ; Steinkopff [u.a.] ; Springer-Medizin-Verl.","publisherPlace":"[Darmstadt] ; Berlin ; Heidelberg [u.a.] ; Darmstadt ; Heidelberg","dateIssuedKey":"1974"}],"language":["eng","ger"],"physDesc":[{"extent":"Online-Ressource"}],"id":{"issn":["1432-1459"],"eki":["242065155"],"zdb":["1421299-7"]},"type":{"media":"Online-Ressource","bibl":"periodical"},"part":{"volume":"266","issue":"1","extent":"9","text":"266(2019), 1, Seite 165-173","year":"2019","pages":"165-173"},"recId":"242065155","disp":"Efficacy and safety of alemtuzumab versus fingolimod in RRMS after natalizumab cessationJournal of neurology"}],"person":[{"family":"Pfeuffer","given":"Steffen","display":"Pfeuffer, Steffen","roleDisplay":"VerfasserIn","role":"aut"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Schmidt, René","family":"Schmidt","given":"René"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Straeten, Frederike Anne","family":"Straeten","given":"Frederike Anne"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Pul, Refik","given":"Refik","family":"Pul"},{"family":"Kleinschnitz","given":"Christoph","display":"Kleinschnitz, Christoph","roleDisplay":"VerfasserIn","role":"aut"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Wieshuber, Marinus","given":"Marinus","family":"Wieshuber"},{"family":"Lee","given":"De-Hyung","display":"Lee, De-Hyung","roleDisplay":"VerfasserIn","role":"aut"},{"display":"Linker, Ralf","family":"Linker","given":"Ralf","role":"aut","roleDisplay":"VerfasserIn"},{"display":"Doerck, Sebastian","given":"Sebastian","family":"Doerck","role":"aut","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","role":"aut","family":"Straeten","given":"Vera","display":"Straeten, Vera"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Windhagen, Susanne","family":"Windhagen","given":"Susanne"},{"family":"Pawlitzki","given":"Marc","display":"Pawlitzki, Marc","roleDisplay":"VerfasserIn","role":"aut"},{"display":"Aufenberg, Christoph","given":"Christoph","family":"Aufenberg","role":"aut","roleDisplay":"VerfasserIn"},{"display":"Lang, Michael","family":"Lang","given":"Michael","role":"aut","roleDisplay":"VerfasserIn"},{"display":"Eienbroeker, Christian","family":"Eienbroeker","given":"Christian","role":"aut","roleDisplay":"VerfasserIn"},{"display":"Tackenberg, Björn","family":"Tackenberg","given":"Björn","role":"aut","roleDisplay":"VerfasserIn"},{"display":"Limmroth, Volker","given":"Volker","family":"Limmroth","role":"aut","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","role":"aut","given":"Brigitte","family":"Wildemann","display":"Wildemann, Brigitte"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Haas, Jürgen","given":"Jürgen","family":"Haas"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Klotz, Luisa","family":"Klotz","given":"Luisa"},{"family":"Wiendl","given":"Heinz","display":"Wiendl, Heinz","roleDisplay":"VerfasserIn","role":"aut"},{"given":"Tobias","family":"Ruck","display":"Ruck, Tobias","roleDisplay":"VerfasserIn","role":"aut"},{"display":"Meuth, Sven G.","given":"Sven G.","family":"Meuth","role":"aut","roleDisplay":"VerfasserIn"}],"name":{"displayForm":["Steffen Pfeuffer, Rene Schmidt, Frederike Anne Straeten, Refik Pul, Christoph Kleinschnitz, Marinus Wieshuber, De-Hyung Lee, Ralf A. Linker, Sebastian Doerck, Vera Straeten, Susanne Windhagen, Marc Pawlitzki, Christoph Aufenberg, Michael Lang, Christian Eienbroeker, Björn Tackenberg, Volker Limmroth, Brigitte Wildemann, Jürgen Haas, Luisa Klotz, Heinz Wiendl, Tobias Ruck, Sven G. Meuth"]},"recId":"1668943085","title":[{"title":"Efficacy and safety of alemtuzumab versus fingolimod in RRMS after natalizumab cessation","title_sort":"Efficacy and safety of alemtuzumab versus fingolimod in RRMS after natalizumab cessation"}],"language":["eng"],"origin":[{"dateIssuedKey":"2019","dateIssuedDisp":"2019"}],"id":{"doi":["10.1007/s00415-018-9117-z"],"eki":["1668943085"]},"note":["Published online: 16 November 2018","Gesehen am 10.07.2019"],"physDesc":[{"extent":"9 S."}]} | ||
| SRT | |a PFEUFFERSTEFFICACYAN2019 | ||